View Older Stories View More Recent Stories
-
HEXO Launches New At-the-Market Offering
-
Hayward (HAYW) Prices Secondary Offering of 24,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
-
Hayward Holdings Announces Pricing of Secondary Offering of 24,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
-
BMO Capital Reiterates Market Perform Rating on Biogen (BIIB), "Encouraged with Potential New Leadership... Remain on Sidelines Given Risk Into Lecanemab Data"
-
BMO Capital Upgrades Sundial Growers (SNDL) to Market Perform Following Recent Decline
-
UPDATE: BMO Capital Upgrades JAKKS Pacific (JAKK) to Outperform
-
Royalty North Strengthens Copper Portfolio with Proposed Acquisition of Antamina NPI as Part of Previously Announced Reverse Takeover Transaction with Sandstorm Gold
-
Fertilizer sector set for biggest profits in years on Russia-Ukraine conflict
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $92 at BMO Capital on Camzyos Approval
-
SANDSTORM GOLD ROYALTIES ANNOUNCES US$1.1 BILLION PORTFOLIO TRANSFORMATION THROUGH ACQUISITIONS OF NOMAD ROYALTY COMPANY AND BASECORE PORTFOLIO
-
UPDATE: BMO Capital Downgrades Weyerhaeuser (WY) to Market Perform
-
MCC Toronto Announces Naming of Paul Austin Human Rights Centre
-
UPDATE: Amazon.com (AMZN) PT Lowered to $3,450 at BMO Capital After Margin Expansion is Pushed Out
-
BMO Capital Reiterates Outperform Rating on Bristol-Myers Squibb Co. (BMY)
-
T. Rowe Price (TROW) PT Lowered to $160 at BMO Capital
-
UPDATE: Twitter, Inc. (TWTR) PT Raised to $54 at BMO Capital
-
Dollar dips, U.S. stocks tumble on inflation concerns
-
BMO Capital Reiterates Market Perform Rating, $64 Price Target on Gilead Sciences (GILD) Following Q1 Report, "Continue to See Gilead at a Crossroads"
-
Gilead earnings beat Street estimates, writedown taken on cancer drug
-
Orchid Island Capital Announces First Quarter 2022 Results
-
Ashland Inc. (ASH) PT Raised to $129 at BMO Capital
-
BMO Capital Reiterates Outperform Rating, $330 Price Target on Eli Lilly (LLY) on Earnings, Highlights "Strong Obesity Data"
-
Tech Giants Commit Nearly $1 Billion Toward Carbon Capture
-
U.S. economy shrinks in first quarter; trade, inventories mask underlying strength
-
BMO Capital Reiterates Market Perform Rating, $263 Price Target on Amgen (AMGN) Following Q1 Report, "Still See Pricing Headwinds Impacting Core Franchises"
-
Checkpoint Software (CHKP) PT Lowered to $155 at BMO Capital
-
UPDATE: Alphabet (GOOGL) PT Lowered to $3,000 at BMO Capital After YouTube Disappointed...Again
-
Microsoft (MSFT) PT Raised to $345 at BMO Capital
-
Atalaya Mining PLC Announces Publication of Site Visit Presentation
-
Kinross Gold (KGC) PT Raised to $9.75 at BMO Capital on Chirano Sale
-
Universal Forest Products (UFPI) PT Raised to $88 at BMO Capital
-
AGP Group Announces US$250 Million Expansion Debt Funding
-
Microsoft (MSFT) PT Lowered to $340 at BMO Capital
-
UPDATE: BMO Capital Starts Expensify Inc (EXFY) at Outperform
-
Atalaya Mining PLC Announces Publication of Inaugural Sustainability Report
-
SmartStop Self Storage REIT, Inc. Files Registration Statement to Pursue Underwritten Public Offering in Conjunction With the Intended Listing of Its Common Stock on the New York Stock Exchange
-
BMO Celebrates Earth Day with Trees from Trades
-
Credit Card Points with Impact: BMO Celebrates Earth Day with New Launch for Cardholders
-
Meta Platforms Inc. (FB) PT Lowered to $225 at BMO Capital
-
The Blackstone Group (BX) PT Raised to $142 at BMO Capital Following Earnings
-
Freeport-McMoRan (FCX) PT Lowered to $56 at BMO Capital
-
BMO Capital Raises Alphabet (GOOGL) Top Line Estimates on Cloud Strength
-
Sibyane Stillwater (SBSW) PT Lowered to $22 at BMO Capital
-
Alcoa (AA) PT Lowered to $95 at BMO Capital
-
Rogers Communications (RCI/B:CN) (RCI) PT Raised to Cdn$80 at BMO Capital
-
Omnicom Group (OMC) PT Raised to $89 at BMO Capital
-
Filo Mining Corp (FIL:CN) (FLMMF) PT Raised to Cdn$28 at BMO Capital
-
The Flowr Corporation Announces Sale of Holigen Holdings for $35 million
-
Multiple inflation pressures complicate Bank of Canada's soft landing goal
-
BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN) Following Checkmate (CMPI) Acquisition

